Melanoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

24 of 59+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F32

  Investigating the mechanisms of KLRG1-mediated immune suppression in regulatory T cells

  Brown University· Providence, United States· US$79,780 awarded in fiscal year 2026· until Oct 2029

• ALLCDC NCCDPHP · R43

  Parents and Schools for Sun Safety (PASS): A Family-Based Skin Cancer Prevention Program for Schools

  Klein Buendel, Inc.· Lakewood, United States· US$311,239 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R21

  Optimizing TIL Harvest Site and Patient Selection with CD8-PET Imaging

  University of Tx Md Anderson Can Ctr· Houston, United States· US$421,685 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R00

  Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides

  Beckman Research Institute/City of Hope· Duarte, United States· US$249,000 awarded in fiscal year 2026· until Aug 2029

• NIH NIA · R43

  RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology

  Ora Biomedical, Inc.· Tukwila, United States· US$299,783 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma (LPS-Pro)

  Universita Degli Studi di Napoli Federico Ii· Napoli, Italy· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spain· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults (PhotoMel)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €5,709,196· until Aug 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SPAtial single-CEll omics research training for MELanoma precision medicine (SPACE-MEL)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €4,565,428· until Aug 2030· 9 countries

10 of 1,011 running projects, newest first. Listed amounts together: US$571.0m + €83.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Updated 19 Oct 2026

  “On hold pending planned interim analysis.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Updated 19 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Suspended

  Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

  NCT05264974· University of Florida· Updated 17 Sept 2026

  “seeking additional funding”Registry text, quoted unchanged. Source

• Terminated

  Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

  NCT05764395· Vanderbilt-Ingram Cancer Center· Updated 16 Sept 2026

  “Drug unavailable”Registry text, quoted unchanged. Source

• Terminated

  High Dose IL-2 in Combination With Anti-PD-1

  NCT03991130· Gregory Daniels· Updated 6 Aug 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· UNICANCER· Updated 3 Aug 2026

  “The study was terminated prematurely due to insufficient patient recruitment”Registry text, quoted unchanged. Source

• Terminated

  Defining the Role of the Skin Microbiome in Immune-related Adverse Events

  NCT04734704· University Hospital, Bordeaux· Updated 23 Jun 2026

  “target number of patients not reached and disabling team changes”Registry text, quoted unchanged. Source

• Terminated

  Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

  NCT04955743· Yale University· Updated 4 Jun 2026

  “Lack of activity in the drugs”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Source

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  NCT06961006· Merck Sharp & Dohme LLC· Source

• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Regeneron Pharmaceuticals· Source

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Regeneron Pharmaceuticals· Source

• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

  NCT07281924· University of Wisconsin, Madison· Source

• The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Source

• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

  NCT06784648· BioInvent International AB· Source

• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

  NCT04835805· Genentech, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 107
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Cancer morbidity and mortality in individuals with obsessive-compulsive disorder: a population-based and sibling cohort study in Sweden and Denmark.

  BMC Med, Nov 2026

• A population-based cohort study of fracture risk among 122 255 adults before and after cancer diagnosis compared with matched controls.

  J Bone Miner Res, Oct 2026

• Biopsy Type and Metastatic Recurrence in Melanoma: A Cohort Study.

  J Drugs Dermatol, Oct 2026

• Skin cancer mortality in Australian and New Zealand kidney transplant recipients: a population-based cohort study using linked health data, 1990-2019.

  Br J Dermatol, Sept 2026

• Beta Testing an mHealth Symptom Management Intervention for People With Advanced Cancer: Single-Cohort Feasibility and Acceptability Study.

  JMIR Cancer, Sept 2026

• Profiling immune check point inhibitors - Induced arthritis: A systematic review and pooled analyses of cohort studies.

  J Autoimmun, Sept 2026

• BRIDGE-KO: auditable transfer learning with bridged knockoffs improves cross-cohort microbiome prediction of immunotherapy response.

  Brief Bioinform, Sept 2026

• Risk of subsequent primary melanoma in 68 002 five-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup cohort study.

  J Natl Cancer Inst, Sept 2026

• [99mTc]Tc-Tilmanocept sentinel node biopsy and long-term outcomes in melanoma: A cohort study and literature review.

  Eur J Surg Oncol, Aug 2026

• De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.

  Clin Infect Dis, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.